Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 AMIX | Healthcare | $1.37 | 203.29K | $2.77M | -0.07 | ― | Moderate Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| AMIX | Autonomix Medical, Inc. | 1.37 | -13.90 | -91.03% |
| Name | Price | % Change | |
|---|---|---|---|
| AMIX | $1.37 | -91.03% |
Autonomix (AMIX) Medical announced the issuance of U.S. Patent No. 12,793,841, titled “Medical Devices With Circuitry For Capturing And Processing Physiological Signals,” that it says “further strengthens” the company’s intellectual
Autonomix Medical, Inc. ( ($AMIX) ) has issued an announcement. At its October 29, 2026 annual meeting, Autonomix Medical said 905,610 shares, or approximately 46% of outstanding shares, voted, establishing
Autonomix (AMIX) Medical announced the Canadian Intellectual Property Office, CIPO, has issued Canadian Patent No. 3,183,802, titled, “Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within and/or Through
Autonomix (AMIX) Medical announced the successful completion of a pre-submission meeting with the U.S. Food and Drug Administration, FDA, regarding the Company’s recently announced standalone transvascular sensing platform, which is
Autonomix (AMIX) Medical announced the grant of European Patent No. EP 4 233 700 B1, titled “Systems for Assessing Neural Activity in an Eye.” “This European patent represents another important
Autonomix Medical, Inc. ( ($AMIX) ) has issued an update. On September 14, 2026, Autonomix Medical’s board expanded from five to six directors and appointed former Medtronic Vice President and
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.07M shares of common stock. The company is not selling any
Autonomix Medical, Inc. ( ($AMIX) ) just unveiled an update. On August 24, 2026, Autonomix Medical entered into a warrant inducement agreement with an investor holding July 2026 warrants, leading
Autonomix (AMIX) announced the issuance of U.S. Patent No. 12,714,780 by the United States Patent and Trademark Office, or USPTO, titled “Systems and Methods for Regulating Organ and/or Tumor Growth
Autonomix (AMIX) Medical announced the successful completion of its Good Laboratory Practice preclinical study, a significant regulatory milestone supporting the company’s submission to the FDA. The study was conducted in
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| AMIX | buy | Reiterated | Oct 16, 2026 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
